“From Diagnosis to Endocrine Management: Utilizing Genomic Profiling to Inform Comprehensive Treatment Planning for Women With Early Stage Breast Cancer”


Upon completion of this webinar, participants should be able to:

  • Understand the latest data supporting the utility of Agendia’s assays: MammaPrint® and BluePrint® for ER+ patients.
  • Review and appreciate the real-world impact of MammaPrint and BluePrint.
  • Recommend genomic profiling for pre-and post-operative breast cancer treatment planning


Recorded on Thursday 30th September – 11 AM EST

View The Recorded Webinar Here

About the speakers

William Audeh, MD, MS
Chief Medical Officer, Agendia
William Audeh, MD, MS is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics and targeted cancer therapy.

Alberto Montero, MD, MBA, CPHQMD

Alberto Montero, MD, MBA, CPHQ, is clinical director of the Breast Cancer Medical Oncology Program at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University School of Medicine. He is board certified in medical oncology by the American Board of Internal Medicine. Dr. Montero has been in academic practice for over 13 years and has demonstrated a strong track record of clinical research in breast cancer. Prior to joining the UH Seidman Cancer Center team, Dr. Montero spent seven years at the Cleveland Clinic, where he served as a staff physician in the hematology and oncology department, as well as chief quality improvement officer and patient experience officer. Before that, Dr. Montero was on staff at University of Miami Sylvester Cancer Center as Breast Cancer Site Disease Group co-leader, and at the Medical University of South Carolina Division of Hematology/Oncology.


Trusted by leading physicians and institutions around the world

Our Tests

At the genomic level, physicians can examine the activity of specific genes inside a tumor – how they interact to drive the behavior of a tumor.

View More Information
Genomic Testing Cell Photo

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

View More Information
Two women reading about genomic breast cancer results

Latest News

The most recent data and news from Agendia to keep you up-to-date on how our tests can support you and your patients.

Read the article